Strides Pharma Acquires Amexel to Strengthen Pharma Collaborations in Southeast Asia

The acquisition involves a 100% stake in Amexel, with the transaction valued at a nominal sum of $10.

Strides Pharma Global (SPG), a step-down subsidiary of Strides Pharma Science Limited, has announced its acquisition of Amexel, a Singapore-based company, as part of its strategy to strengthen collaborations among pharmaceutical manufacturers and suppliers across India, China, and Southeast Asia.

The acquisition involves a 100% stake in Amexel, with the transaction valued at a nominal sum of $10.

This move comes as part of Strides Pharma’s broader efforts to create a business platform that promotes introductions, collaborations, procurement, and business engagement between pharmaceutical manufacturers and suppliers in key Asian markets.

As a result of this acquisition, Amexel will serve as the dedicated entity for this new business initiative, focusing on increasing access to high-quality pharmaceutical products and strengthening regional partnerships.

Fostering Regional Collaborations

As a wholly owned subsidiary of SPG, Amexel will play a central role in driving growth in Strides’ pharmaceutical manufacturing capabilities. The company is set to focus on in-licensing and technology transfers to enhance Strides' existing manufacturing facilities in India, its affiliates, and partner manufacturers. Additionally, Amexel will contribute to sourcing active pharmaceutical ingredients, raw materials, and packaging materials, ensuring a stable supply chain for Strides’ operations.

The acquisition also aims to build strategic alliances with distributors, commercial partners, and customers, facilitating the distribution and commercialization of pharmaceutical products across the three regions.

Amexel is expected to generate revenue through facilitation services and will implement a profit-sharing model tied to the commercialization of products.